Cochlear Implant Trial Shows Preserving Natural Low-Frequency Hearing Improves Speech Understanding in Noise

In a multicenter U.S. feasibility trial, adults who kept their natural low-frequency hearing after receiving a slim cochlear implant electrode improved their speech recognition scores by 22 to 54 percentage points within a year.

Many adults with hearing loss do not lose all frequencies equally. A common pattern, especially with age, is a sloping loss: the low pitches that carry the melody and rhythm of speech remain relatively intact, while the high pitches that carry consonant clarity fade away. People with this pattern often say they can hear that someone is talking but cannot make out the words.

For years, cochlear implant surgery risked destroying whatever natural hearing remained in the implanted ear. A new multicenter trial, published in Audiology and Neurotology and indexed on PubMed this week, tested whether a slim electrode could preserve that residual low-frequency hearing while still delivering the benefits of electrical stimulation.

Background: Why the Researchers Looked at This

Cochlear implants were historically reserved for people with profound deafness. Indications have expanded, and adults with substantial residual low-frequency hearing are now increasingly considered for implantation. That creates a delicate engineering problem: the electrode must be threaded into the cochlea, the spiral-shaped hearing organ, without damaging the delicate structures that still detect low-pitched sound.

When natural hearing survives the surgery, patients can use what audiologists call electric-acoustic stimulation. The implant electrically delivers the high frequencies the ear can no longer hear, while a built-in acoustic component amplifies the low frequencies the ear still detects naturally. Combining the two tends to produce richer, more natural sound than electrical stimulation alone.

The researchers wanted to know whether a slim perimodiolar electrode, a thin array designed to hug the inner wall of the cochlea, could reliably preserve low-frequency hearing in this newer, better-hearing candidate group, and whether that preservation would translate into meaningful real-world benefit.

How the Study Was Done

Ten adults were enrolled at three U.S. tertiary centers. To qualify, participants needed low-frequency thresholds of 50 decibels or better at 500 Hz in the ear to be implanted, a sloping high-frequency loss, and word recognition scores of 60 percent or lower on a standard test even with a well-fitted hearing aid. In plain terms, these were people whose hearing aids were no longer enough for clear speech, but who still had usable natural hearing in the low pitches.

Each participant received the CI632 slim perimodiolar implant and was followed for 12 months after activation. The team measured hearing thresholds by air and bone conduction, electrode impedances, word recognition in quiet, sentence understanding in background noise, and patient-reported outcomes. CT scans after surgery verified exactly where each electrode sat inside the cochlea.

What the Researchers Found

The headline result was that low-frequency hearing largely survived the surgery. The average low-frequency pure-tone average (125 to 500 Hz) shifted by 19.3 decibels at activation and remained essentially stable at 22.4 decibels at 12 months. A shift of that size means some natural hearing was sacrificed, but far less than the total loss that older electrode designs often caused.

Because usable acoustic hearing was preserved, all ten participants were able to use electric-acoustic stimulation in the implanted ear. None had to rely on electrical stimulation alone.

Speech understanding improved substantially. Across the different tests, average improvement at 12 months ranged from 22 to 54 percentage points, and patient-reported outcomes improved alongside the laboratory measures. The authors note that preserved low-frequency hearing contributed strongly to improved speech understanding in noise, the situation hearing-impaired listeners find hardest.

Imaging confirmed that every electrode ended up in the scala tympani, the intended chamber of the cochlea, with a mean insertion depth of 406.6 degrees. Electrode impedances stayed stable across visits, suggesting the implants were functioning consistently.

What It Means for People with Hearing Loss

The study reinforces a principle that runs through modern hearing care: natural hearing is worth protecting, even small amounts of it. Low frequencies carry voice pitch, intonation, and the cues that help the brain separate one voice from a noisy background. Participants in this trial did not just hear more, they understood more, especially in noise, because the technology worked with their remaining natural hearing rather than replacing it wholesale.

For people with severe sloping losses who no longer benefit from hearing aids, the findings suggest that implantation under expanded indications can be done without giving up residual hearing. For the much larger group of people with milder loss, the same logic argues for acting earlier, while more natural hearing remains to build on.

Why Clearer Speech in Noise Matters at Every Level of Hearing Loss

This trial involved surgical implants for people whose loss had progressed beyond what hearing aids could help. It is worth noting that over-the-counter devices are approved for mild-to-moderate hearing loss, and severe or profound loss still benefits most from clinical fittings like the ones in this study.

For adults whose loss is still in the mild-to-moderate range, the study's central lesson applies at a smaller scale: understanding speech in noise is the problem that matters most, and processing that supports it makes the difference. Newer FDA-OTC hearing aids are built around that goal. Panda Quantum is one example, a 16-channel WDRC device with adaptive noise reduction designed for clearer speech in noisy environments, plus Bluetooth for calls, TV, and music.

Quantum also offers an optional app-based in-ear hearing test that can personalize gain and frequency response to the user's hearing profile, though the device works out of the box without the app or the test. It runs 20 hours per charge with a case that provides three additional full charges, and comes with a 5-year warranty and a 45-day trial that starts when the customer receives the product. Details are at pandahearing.com.

Limitations of This Research

This was a feasibility trial with only ten participants, no control group, and an open-label design, meaning both patients and clinicians knew what device was implanted. Results from small single-arm studies can look stronger than they prove to be in larger randomized trials. The 12-month window also cannot show whether preserved hearing remains stable over many years.

The PubMed record does not detail funding sources or conflicts of interest for this trial, which readers should keep in mind when weighing results involving a specific commercial implant.

Where This Leaves Us

Hearing technology keeps moving toward the same destination from different directions: preserve what nature still provides, and add only what is missing. Whether the tool is a surgical implant with electric-acoustic stimulation or an amplification device fitted early, the evidence increasingly favors acting while residual hearing is still there to work with.

Mowry S, Cullen R, Sydlowski S, Rivas A, Ursick J, Woodson E, Tejani VD, Lewis K, Reinhart P. Hearing preservation and efficacy outcomes in CI632 recipients with sloping high-frequency hearing loss: Multicenter trial results. Audiology and Neurotology. 2026. Retrieved from PubMed. https://doi.org/10.1159/aud/abnag004